CMS Medicare Research 
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study.” said Peter Altman , PhD.,
DAIC
JANUARY 30, 2025
29, 2025 Researchers atOchsner Health, led byHernan Bazan, MD, DFSVS, FACS, have developed a predictive model with a 93% accuracy rate in determining whether urgent carotid-intervention patients will regain functional independence. tim.hodson Thu, 01/30/2025 - 15:31 Jan.
DAIC
JUNE 4, 2024
In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.
DAIC
MARCH 7, 2024
The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.
DAIC
JULY 25, 2024
The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.
DAIC
DECEMBER 8, 2023
The company recently announced it has received CMS approval for Medicare coverage during the DRAIN-HF pivotal trial. We look forward to working with our investigators and research teams to advance the scientific evidence around this groundbreaking technology." Fain, MD , President and Chief Executive Officer, Procyrion. "We
DAIC
MAY 2, 2024
The clinical research results presented for the roll-in cohort from our CardiAMP CMI Trial highlight BioCardia’s continuing efforts to transform the treatment paradigm in refractory angina through the promise of a one-time cost effective minimally invasive autologous cell-based therapy,” said Peter Altman , President and CEO.
Expert insights. Personalized for you.
111 
Let's personalize your content